{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:22:46Z","timestamp":1760242966036},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.humpath.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T15:58:48Z","timestamp":1532015928000},"page":"138-147","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma"],"prefix":"10.1016","volume":"81","author":[{"given":"Song","family":"Hui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Guo-Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Xiao-Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Chun-Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Yu-Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Dong-Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.07.003_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008","volume":"19","author":"Henley","year":"2013","journal-title":"Int J Occup Environ Health"},{"key":"10.1016\/j.humpath.2018.07.003_bb0010","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.surg.2013.01.001","article-title":"Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma","volume":"153","author":"Alexander","year":"2013","journal-title":"Surgery"},{"key":"10.1016\/j.humpath.2018.07.003_bb0020","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0025","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1245\/s10434-013-3077-4","article-title":"Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study","volume":"20","author":"Hommell-Fontaine","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1245\/s10434-012-2651-5","article-title":"A novel nomogram for peritoneal mesothelioma predicts survival","volume":"20","author":"Schaub","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0035","first-page":"867","article-title":"Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67","volume":"138","author":"Gerdes","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182107","article-title":"CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer","volume":"12","author":"Sim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2018.07.003_bb0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10120-003-0246-3","article-title":"Evaluation of malignancy using Ki-67 labeling index for gastric stromal tumor","volume":"6","author":"Nagasako","year":"2003","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.humpath.2018.07.003_bb0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncy.20071","article-title":"The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions","volume":"118","author":"Hasteh","year":"2010","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0055","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12253-009-9170-0","article-title":"Differential expression of Ki-67 and sex steroid hormone receptors between genders in peritoneal mesothelioma","volume":"15","author":"Chua","year":"2009","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.humpath.2018.07.003_bb0060","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bjc.2015.9","article-title":"Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study","volume":"112","author":"Ghanim","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2018.07.003_bb0065","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1128\/MCB.19.2.1262","article-title":"A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development","volume":"19","author":"Nielsen","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.humpath.2010.06.003","article-title":"The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology","volume":"42","author":"Findeis-Hosey","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0075","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nsb1294-871","article-title":"Solution structure of the ets domain of Fli-1 when bound to DNA","volume":"1","author":"Liang","year":"1994","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0080","first-page":"551","article-title":"Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma","volume":"7","author":"Davidson","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.07.003_bb0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PAS.0b013e31826ab1c0","article-title":"IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations","volume":"37","author":"Lee","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2018.07.003_bb0095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/MCB.23.2.482-492.2003","article-title":"Alteration of mesodermal cell differentiation by EWS\/FLI-1, the oncogene implicated in Ewing's sarcoma","volume":"23","author":"Eliazer","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0100","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2018.07.003_bb0105","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","article-title":"A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database","volume":"117","author":"Yan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2018.07.003_bb0110","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.humpath.2009.04.030","article-title":"IMP3\/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3\/L523S in effusion cytology","volume":"41","author":"Ikeda","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0115","first-page":"1309","article-title":"Fli-1 expression in malignant melanoma","volume":"23","author":"Torlakovic","year":"2008","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0120","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","article-title":"Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"49","author":"Baratti","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2018.07.003_bb0125","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.athoracsur.2016.08.063","article-title":"Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma","volume":"103","author":"Vigneswaran","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.humpath.2018.07.003_bb0130","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","article-title":"Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy","volume":"21","author":"Feldman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0135","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/sj.bjc.6604951","article-title":"Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study","volume":"100","author":"Berney","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2018.07.003_bb0140","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/bjc.2015.239","article-title":"Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor\u2013positive, HER2-negative breast carcinoma","volume":"113","author":"Rossi","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2018.07.003_bb0145","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/leu.2009.20","article-title":"Continuous Fli-1 expression plays an essential role in the proliferation and survival of F-MuLV\u2013induced erythroleukemia and human erythroleukemia","volume":"23","author":"Cui","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.07.003_bb0150","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tranon.2014.04.015","article-title":"Friend leukemia virus integration 1 expression has prognostic significance in nasopharyngeal carcinoma","volume":"7","author":"Liang","year":"2014","journal-title":"Transl Oncol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0155","first-page":"3387","article-title":"IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression","volume":"9","author":"Zhu","year":"2017","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.humpath.2018.07.003_bb0160","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00432-014-1850-9","article-title":"IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status","volume":"140","author":"Damasceno","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0165","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1309\/AJCP5KNL7QTELLYI","article-title":"Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells","volume":"141","author":"Minato","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2018.07.003_bb0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000442092","article-title":"Use of anti-Noxa antibody for differential diagnosis between epithelioid mesothelioma and reactive mesothelial hyperplasia","volume":"83","author":"Kushitani","year":"2016","journal-title":"Pathobiology"},{"key":"10.1016\/j.humpath.2018.07.003_bb0175","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/dc.21398","article-title":"Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations","volume":"39","author":"Ikeda","year":"2011","journal-title":"Diagn Cytopathol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718302600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718302600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T21:25:28Z","timestamp":1541712328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817718302600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":35,"alternative-id":["S0046817718302600"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.07.003","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}